CN1730067A - 一种治疗血证的分散片及其制备方法和用途 - Google Patents
一种治疗血证的分散片及其制备方法和用途 Download PDFInfo
- Publication number
- CN1730067A CN1730067A CN 200510020760 CN200510020760A CN1730067A CN 1730067 A CN1730067 A CN 1730067A CN 200510020760 CN200510020760 CN 200510020760 CN 200510020760 A CN200510020760 A CN 200510020760A CN 1730067 A CN1730067 A CN 1730067A
- Authority
- CN
- China
- Prior art keywords
- dispersible tablet
- adjuvant
- callicarpa nudiflora
- extract
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims description 29
- 239000008280 blood Substances 0.000 title claims description 13
- 210000004369 blood Anatomy 0.000 title claims description 13
- 208000011580 syndromic disease Diseases 0.000 title 1
- 241000404844 Callicarpa nudiflora Species 0.000 claims abstract description 41
- 239000000284 extract Substances 0.000 claims abstract description 38
- 239000003826 tablet Substances 0.000 claims abstract description 17
- 229930003944 flavone Natural products 0.000 claims abstract description 13
- 235000011949 flavones Nutrition 0.000 claims abstract description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 28
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 27
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 27
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 26
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 26
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 26
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 26
- 235000010357 aspartame Nutrition 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 24
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 24
- 108010011485 Aspartame Proteins 0.000 claims description 21
- 239000000605 aspartame Substances 0.000 claims description 21
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 21
- 229960003438 aspartame Drugs 0.000 claims description 21
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 19
- 208000019838 Blood disease Diseases 0.000 claims description 18
- 208000014951 hematologic disease Diseases 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 12
- 208000032843 Hemorrhage Diseases 0.000 claims description 12
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 12
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 12
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 12
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 12
- 235000005493 rutin Nutrition 0.000 claims description 12
- 229960004555 rutoside Drugs 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 5
- 150000002212 flavone derivatives Chemical class 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 229940109275 cyclamate Drugs 0.000 claims description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 3
- 208000035861 hematochezia Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 240000003690 Callicarpa japonica Species 0.000 description 19
- 235000017595 Callicarpa japonica Nutrition 0.000 description 19
- 239000000047 product Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 201000009442 piebaldism Diseases 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229960004817 etamsylate Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000000025 haemostatic effect Effects 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002315 pressor effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
处方 | 浸膏粉(g) | MCC(g) | 乳糖(g) | PVPP(g) | CCMC-Na(g) | LS-HPC(g) | CMS-Na(g) | 90%乙醇(g) | 微粉硅胶(g) |
123456789101112 | 2.52.52.52.52.52.52.52.52.52.52.52.5 | 222222////// | //////222222 | 0.5////0.250.5////0.25 | /0.5//0.25//0.5//0.25/ | //0.5//0.25//0.5//0.25 | ///0.50.25////0.50.25/ | 适量适量适量适量适量适量适量适量适量适量适量适量 | 0.0250.0250.0250.0250.0250.0250.0250.0250.0250.0250.0250.025 |
处方编号 | 考察项目 | |||
压片情况 | 外观性状 | 崩解时限(min) | 分散均匀性 | |
123456789101112 | 可压性均较好,不粘冲 | 片面平滑 | 510142087612152098 | 全部通过2号筛有不能通过2号筛的颗粒有不能通过2号筛的颗粒有不能通过2号筛的颗粒全部通过2号筛全部通过2号筛全部通过2号筛有不能通过2号筛的颗粒有不能通过2号筛的颗粒有不能通过2号筛的颗粒有不能通过2号筛的颗粒全部通过2号筛 |
处方 | 13 | 14 | 15 |
浸膏粉(g)微晶纤维素(g)交联聚维酮(g)90%乙醇溶液微粉硅胶(g) | 2.51.750.75适量0.025 | 2.51.51适量0.025 | 2.51.251.25适量0.025 |
处方 | 考察项目 | |||
压片情况 | 外观性状 | 崩解时限(s) | 分散均匀性 | |
131415 | 可压性好,不粘冲 | 片面平滑 | 255182124 | 全部能通过2号筛 |
矫味剂种类 | 用量 | 口感 | 崩解时限(S) |
甜菊甙甜蜜素阿斯巴甜 | 0.40.50.60.1%0.2%0.3%0.5%1%1.5% | 一般有异味有异味一般一般一般一般较好好 | 130135143129131133125128158 |
加入法 | 外观性状 | 崩解时限(s) | 分散均匀性 |
内加法外加法内加30%,外加70%内加50%,外加50%内加70%,外加30% | 片面平滑,无花斑片面粗糙,有花斑片面粗糙,有花斑片面粗糙,有花斑片面平滑,有花斑 | 12695116107120 | 可全部通过2号筛可全部通过2号筛可全部通过2号筛可全部通过2号筛可全部通过2号筛 |
助流剂种类 | 用量(%) | 外观 | 崩解时限(S) |
微粉硅胶硬脂酸镁 | 0.511.50.1%0.3%0.5% | 素片外观平滑,但光洁度一般素片外观平滑,但光洁度一般素片外观平滑,但光洁度一般素片外观平滑,但光洁度一般素片外观平滑,光洁度较好素片外观平滑,光洁度较好 | 115120124118122167 |
批号 | 编号 | 累计溶出百分率(%) | |||||||
1min | 3min | 5min | 10min | 15min | 20min | 30min | 45min | ||
031201 | 123456 | 67.7670.2163.6867.3569.6062.66 | 77.8275.8867.4573.5275.4568.64 | 83.4881.6672.9181.4581.8272.91 | 91.4990.8279.0989.1990.5881.95 | 93.9897.9885.2093.6492.6385.32 | 94.13102.2891.5596.0596.6491.51 | 96.02102.7494.4297.3899.6497.38 | 95.42103.8994.6197.11101.91101.77 |
平均(%) | 66.88 | 73.13 | 79.04 | 87.17 | 91.36 | 95.36 | 97.93 | 99.12 | |
RSD(%) | 4.61 | 5.72 | 6.07 | 6.07 | 5.57 | 4.22 | 2.98 | 3.92 |
批号 | 编号 | 累计溶出百分率(%) | |||||||
1min | 3min | 5min | 10min | 15min | 20min | 30min | 45min | ||
031201 | 123456 | 2.612.293.794.033.402.45 | 9.6710.3611.379.6412.2313.29 | 21.7423.6625.3322.5121.4822.51 | 32.3936.5936.4434.7737.2535.64 | 60.4258.7857.2754.4360.9758.34 | 71.8876.5877.5573.6578.0974.45 | 91.25101.5599.4486.4693.8091.63 | 95.42107.00104.2695.1598.3297.22 |
平均(%) | 3.10 | 11.09 | 22.51 | 35.65 | 58.50 | 75.51 | 94.02 | 99.56 | |
RSD(%) | 23.96 | 13.29 | 8.09 | 4.95 | 4.16 | 3.26 | 5.95 | 2.98 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510020760XA CN100441171C (zh) | 2005-04-21 | 2005-04-21 | 一种治疗血证的分散片及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510020760XA CN100441171C (zh) | 2005-04-21 | 2005-04-21 | 一种治疗血证的分散片及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1730067A true CN1730067A (zh) | 2006-02-08 |
CN100441171C CN100441171C (zh) | 2008-12-10 |
Family
ID=35962512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510020760XA Expired - Fee Related CN100441171C (zh) | 2005-04-21 | 2005-04-21 | 一种治疗血证的分散片及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100441171C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101214332B (zh) * | 2008-01-16 | 2010-12-29 | 上海玉森新药开发有限公司 | 治疗喘息性支气管炎和支气管哮喘的组合物及其制备方法 |
CN102935147A (zh) * | 2012-11-29 | 2013-02-20 | 康普药业股份有限公司 | 一种治疗胃出血中成药胃漂浮片及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1672705A (zh) * | 2004-03-25 | 2005-09-28 | 一笑堂(湖南)制药有限公司 | 裸花紫珠分散片及其制备方法 |
CN1562246A (zh) * | 2004-03-31 | 2005-01-12 | 一笑堂(湖南)制药有限公司 | 一种裸花紫珠制剂及其制备方法 |
-
2005
- 2005-04-21 CN CNB200510020760XA patent/CN100441171C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101214332B (zh) * | 2008-01-16 | 2010-12-29 | 上海玉森新药开发有限公司 | 治疗喘息性支气管炎和支气管哮喘的组合物及其制备方法 |
CN102935147A (zh) * | 2012-11-29 | 2013-02-20 | 康普药业股份有限公司 | 一种治疗胃出血中成药胃漂浮片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100441171C (zh) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1248690C (zh) | 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂 | |
CN105412026B (zh) | 盐酸阿考替胺片及其制备方法 | |
CN106491554B (zh) | 一种阿托伐他汀钙片剂及其制备方法 | |
CN111973565A (zh) | 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法 | |
WO2012027968A1 (zh) | 一种三七三醇皂苷肠溶微丸及其胶囊剂和制备方法 | |
CN101991559B (zh) | 一种稳定的阿戈美拉汀胶囊药物组合物 | |
CN107998085A (zh) | 一种含有阿托伐他汀钙碱性固体分散体的片剂及其制备方法 | |
CN1730067A (zh) | 一种治疗血证的分散片及其制备方法和用途 | |
CN1883674A (zh) | 治疗糖尿病的降糖宁制剂及其制备方法 | |
CN106511291A (zh) | 一种盐酸阿考替胺缓释片剂及其制备方法 | |
CN106214646B (zh) | 一种水飞蓟宾葡甲胺制剂 | |
CN105596312B (zh) | 一种磷酸二甲啡烷胶囊组合物及其制备方法 | |
CN109232297A (zh) | 芬乐胺晶b型、制备方法和其组合物与用途 | |
CN1220513C (zh) | 一种止血镇痛、祛瘀生新的中成药及其制备方法 | |
CN105147690A (zh) | 一种治疗泌尿外科类疾病的药物枸橼酸西地那非组合物片剂 | |
CN1891256A (zh) | 一种冠心丹参分散片及其制备方法 | |
CN100586432C (zh) | 一种用于治疗肝病的益肝灵分散片及其制备方法 | |
CN101057939A (zh) | 一种具有清热凉血、化瘀止血的中药制剂及其制备方法 | |
CN110354093A (zh) | 一种枸橼酸莫沙必利药物组合物 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
CN106176659B (zh) | 一种坦度螺酮肠溶片及其制备方法 | |
CN111358795A (zh) | 一种枸橼酸托法替布制剂及其制备方法 | |
CN109010317A (zh) | 一种富马酸替诺福韦二吡呋酯颗粒及其制备方法 | |
CN110604726B (zh) | 一种索非布韦组合物及其应用 | |
CN1389208A (zh) | 苯二氮卓类药物口服脉冲释药系统及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Sichuan Huayu Pharmaceutical Co., Ltd. Assignor: Chengdu Tengxiang Health Industry Co., Ltd. Contract fulfillment period: 2006.8.18 to 2013.8.18 contract change Contract record no.: 2009510000056 Denomination of invention: Dispersible tablet for treating blood syndrome, its preparation method and purposes Granted publication date: 20081210 License type: Exclusive license Record date: 2009.9.21 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.8.18 TO 2013.8.18; CHANGE OF CONTRACT Name of requester: SICHUAN HUAYU PHARMACEUTICAL CO., LTD. Effective date: 20090921 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081210 |
|
RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20100804 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081210 Termination date: 20170421 |